NonAlcoholic Steatohepatitis NASH Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide NonAlcoholic Steatohepatitis NASH Pipeline Review, H2 2019, provides an overview of the NonAlcoholic Steatohepatitis NASH Gastrointestinal pipeline landscape.
Nonalcoholic steatohepatitis NASH is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide NonAlcoholic Steatohepatitis NASH Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for NonAlcoholic Steatohepatitis NASH Gastrointestinal, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The NonAlcoholic Steatohepatitis NASH Gastrointestinal pipeline guide also reviews of key players involved in therapeutic development for NonAlcoholic Steatohepatitis NASH and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in PreRegistration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 50, 48, 1, 7, 158, 62 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.
NonAlcoholic Steatohepatitis NASH Gastrointestinal pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of NonAlcoholic Steatohepatitis NASH Gastrointestinal.
The pipeline guide reviews pipeline therapeutics for NonAlcoholic Steatohepatitis NASH Gastrointestinal by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, RD brief, MoA other developmental activities.
The pipeline guide reviews key companies involved in NonAlcoholic Steatohepatitis NASH Gastrointestinal therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates NonAlcoholic Steatohepatitis NASH Gastrointestinal therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for NonAlcoholic Steatohepatitis NASH Gastrointestinal
Reasons to buy
Procure strategically important competitor information, analysis, and insights to formulate effective RD strategies.
Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for NonAlcoholic Steatohepatitis NASH Gastrointestinal.
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding NonAlcoholic Steatohepatitis NASH Gastrointestinal pipeline depth and focus of Indication therapeutics.
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.